Patents Assigned to VANDA PHARMECEUTICALS INC.
  • Method of treatment based on polymorphisms of the KCNQ1 gene
    Patent number: 10563259
    Abstract: The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: February 18, 2020
    Assignee: VANDA PHARMECEUTICALS, INC.
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • RUTHENIUM (II) CATALYSTS FOR USE IN STEREOSELECTIVE CYCLOPROPANATIONS
    Publication number: 20130023662
    Abstract: Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N?-bis(3,5-di-t-butyl-salicylidene) and RuCl2(p-cymene)]2.
    Type: Application
    Filed: December 12, 2011
    Publication date: January 24, 2013
    Applicant: VANDA PHARMECEUTICALS INC.
    Inventors: David E. Pereira, Wade Aumiller, Raymond Dagger
  • RUTHENIUM (II) CATALYSTS FOR USE IN STEREOSELECTIVE CYCLOPROPANATIONS
    Publication number: 20120149906
    Abstract: Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N?-bis(3,5-di-t-butyl-salicylidene) and RuCl2(p-cymene)]2.
    Type: Application
    Filed: December 12, 2011
    Publication date: June 14, 2012
    Applicant: VANDA PHARMECEUTICALS INC.
    Inventors: David E. Pereira, Wade Aumiller, Raymond Dagger
  • RUTHENIUM (II) CATALYSTS FOR USE IN STEREOSELECTIVE CYCLOPROPANATIONS
    Publication number: 20100228039
    Abstract: Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N?-bis(3,5-di-t-butyl-salicylidene) and RuCl2(p-cymene)]2.
    Type: Application
    Filed: May 20, 2010
    Publication date: September 9, 2010
    Applicant: VANDA PHARMECEUTICALS INC.
    Inventors: David E. Pereira, Wade Aumiller, Raymond Dagger